Last reviewed · How we verify
GS101 injection
At a glance
| Generic name | GS101 injection |
|---|---|
| Sponsor | Jiangsu Genscend Biopharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of GS101 Injection (PHASE1)
- A Phase III Study of GS101 Injection to Dupixent® (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GS101 injection CI brief — competitive landscape report
- GS101 injection updates RSS · CI watch RSS
- Jiangsu Genscend Biopharmaceutical Co., Ltd portfolio CI